Skip to main content
Contact Us
Subscribe
E-Edition
59°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by NuCana plc
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
November 11, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
September 25, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
September 14, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
August 29, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
August 15, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
May 21, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 01, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Announces Completion of ADS Ratio Change
April 16, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
April 09, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Announces Plan to Implement ADS Ratio Change
March 27, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
March 20, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Present at TD Cowen’s 44th Annual Health Care Conference
February 27, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
November 16, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Announces Listing Transfer to Nasdaq Capital Market
November 10, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Participate in the Truist Securities 2023 BioPharma Symposium
November 01, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
October 16, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
October 13, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
September 18, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
August 16, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Present at the Jefferies Healthcare Conference
June 01, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
May 17, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Announces Receipt of Nasdaq Notice
May 12, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
April 14, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
April 04, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
March 24, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
NuCana to Participate in Two Upcoming Investor Conferences
February 28, 2023
From
NuCana plc
Via
GlobeNewswire
Tickers
NCNA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.